ViewRay launches multicenter trial for pancreatic cancer

By staff writers

September 25, 2017 -- Image-guided radiation therapy developer ViewRay launched a multicenter prospective clinical trial using MRIdian for locally advanced unresectable pancreatic cancer.

The study is the first initiative of ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian clinical users focused on evidence gathering to support MR-guided radiation therapy. The trial will study MRIdian's capabilities and associated toxicity, local control, and patient outcomes regarding locally advanced unresectable pancreatic cancer, the company said.

Copyright © 2017

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking